Published in Curr Neuropharmacol on September 01, 2011
Clinical reasoning: progressive visuospatial problems in a 71-year-old man. Neurology (2014) 0.75
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med (2010) 13.82
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med (2010) 13.70
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med (2008) 12.90
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med (2006) 11.29
Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med (2005) 7.54
Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature (1992) 7.20
Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med (2006) 7.18
Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med (2005) 7.04
Primary central nervous system lymphoma in a patient treated with natalizumab. Ann Neurol (2009) 6.96
The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem (2002) 6.96
Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med (2008) 6.86
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood (1994) 6.47
Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med (2005) 6.33
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med (2006) 6.25
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med (2010) 4.08
Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet (2002) 3.74
Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet (1980) 3.71
Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med (1994) 3.42
Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J Infect Dis (2009) 3.23
Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med (2001) 3.10
Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med (1996) 2.61
Intravenous immune globulin therapy for neurologic diseases. Ann Intern Med (1997) 2.57
Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf (2000) 2.37
Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer. Nat Rev Cancer (2008) 2.24
An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology (2008) 2.12
Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis. Neurology (2005) 2.11
Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology (2009) 2.10
Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol (2008) 2.02
JC virus DNA load in patients with and without progressive multifocal leukoencephalopathy. Neurology (1999) 1.97
A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis. Mult Scler (2002) 1.86
Detection of JC virus DNA fragments but not proteins in normal brain tissue. Ann Neurol (2008) 1.82
Mirtazapine in progressive multifocal leukoencephalopathy associated with polycythemia vera. J Infect Dis (2007) 1.79
Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study. Arthritis Rheum (1995) 1.78
Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet (1999) 1.69
Melanoma complicating treatment with natalizumab for multiple sclerosis. N Engl J Med (2008) 1.69
Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation. Transplantation (2004) 1.68
Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. Am J Kidney Dis (2000) 1.68
Mitoxantrone treatment of multiple sclerosis: safety considerations. Neurology (2004) 1.66
Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N Engl J Med (2009) 1.63
Cancers complicating organ transplantation. N Engl J Med (1990) 1.57
Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol (2005) 1.52
Ocular toxoplasmosis during natalizumab treatment. Neurology (2009) 1.51
Sphingosine 1-phosphate induces contraction of coronary artery smooth muscle cells via S1P2. Cardiovasc Res (2003) 1.46
Peroxynitrite-induced cytotoxicity: mechanism and opportunities for intervention. Toxicol Lett (2003) 1.45
Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. Biochem Soc Trans (1997) 1.45
Rituximab therapy in monoclonal IgM-related neuropathies. Leuk Lymphoma (2006) 1.43
Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood (1983) 1.43
Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med (1981) 1.43
A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology (1998) 1.40
Thiopurine-induced liver injury in patients with inflammatory bowel disease: a systematic review. Am J Gastroenterol (2007) 1.39
Pathophysiological aspects of cyclophosphamide and ifosfamide induced hemorrhagic cystitis; implication of reactive oxygen and nitrogen species as well as PARP activation. Cell Biol Toxicol (2007) 1.35
Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am J Transplant (2005) 1.33
Long-term use of IgA-depleted intravenous immunoglobulin in immunodeficient subjects with anti-IgA antibodies. J Clin Immunol (1993) 1.24
Mycophenolic acid for psoriasis. A review of pharmacology, long-term efficacy, and safety. J Am Acad Dermatol (1987) 1.21
Egress: a receptor-regulated step in lymphocyte trafficking. Immunol Rev (2003) 1.16
The treatment of chronic progressive multiple sclerosis with cladribine. Proc Natl Acad Sci U S A (1996) 1.14
Mutagenicity and potential carcinogenicity of thiopurine treatment in patients with inflammatory bowel disease. Cancer Res (2009) 1.09
Immunosuppressive therapies in myasthenia gravis. Autoimmunity (2010) 1.07
Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurology (2002) 1.06
Analysis of PCR as a tool for detection of JC virus DNA in cerebrospinal fluid for diagnosis of progressive multifocal leukoencephalopathy. J Clin Microbiol (1996) 1.06
Therapy-related acute leukaemia with Mitoxantrone: what is the risk and can we minimise it? Mult Scler (2009) 1.06
Clinically significant liver injury in patients treated with natalizumab. Aliment Pharmacol Ther (2010) 1.04
Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab. Muscle Nerve (2006) 1.01
Sphingosine 1-phosphate induces sinus tachycardia and coronary vasoconstriction in the canine heart. Cardiovasc Res (2000) 1.01
Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects. Mult Scler (2002) 1.01
In vitro immunosuppressive effects of mycophenolic acid and an ester pro-drug, RS-61443. Transplant Proc (1991) 1.00
Successful use of rituximab in a patient with Churg-Strauss syndrome and refractory central nervous system involvement. Ann Rheum Dis (2009) 0.99
Clinical study of FK506 in patients with myasthenia gravis. Muscle Nerve (2003) 0.99
Mycophenolate mofetil for myasthenia gravis: an open-label pilot study. Neurology (2001) 0.98
Lysophospholipids and the cardiovascular system. Biochim Biophys Acta (2002) 0.97
Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution. Blood (2002) 0.96
Hemorrhaging focal encephalitis under fingolimod (FTY720) treatment: a case report. Neurology (2009) 0.94
Mitoxantrone: benefits and risks in multiple sclerosis patients. Neurol Sci (2009) 0.94
Mycophenolate mofetil-induced neutropenia in liver transplantation. Transplant Proc (2005) 0.93
Sustained response to Rituximab in anti-AChR and anti-MuSK positive Myasthenia Gravis patients. J Neuroimmunol (2008) 0.92
Rituximab for myasthenia gravis: three case reports and review of the literature. J Neurol Sci (2009) 0.91
Successful treatment of myasthenia gravis with tacrolimus. Muscle Nerve (2002) 0.89
Liver enzyme abnormalities in patients with atopic dermatitis treated with mycophenolate mofetil. Arch Dermatol (2006) 0.89
Cardiac changes with cyclophosphamide. Med Pediatr Oncol (1981) 0.88
Cardiotoxicity in patients treated with mitoxantrone: Southwest Oncology Group phase II studies. Cancer Treat Rep (1987) 0.88
Efficacy of low-dose FK506 in the treatment of Myasthenia gravis--a randomized pilot study. Eur Neurol (2005) 0.87
Wegener granulomatosis with massive intracerebral hemorrhage: remission of disease in response to rituximab. J Clin Rheumatol (2005) 0.87
Azathioprine-associated acute pancreatitis. Am J Dig Dis (1977) 0.87
Mycophenolic acid increases apoptosis, lysosomes and lipid droplets in human lymphoid and monocytic cell lines. Transplantation (1999) 0.87
Successful treatment of refractory generalized myasthenia gravis with rituximab. Eur J Neurol (2009) 0.86
Inflammatory pseudotumor associated with HIV, JCV, and immune reconstitution syndrome. Neurology (2009) 0.85
Rituximab in refractory MuSK antibody myasthenia gravis. J Neurol (2007) 0.85
Review: intravenous immunoglobulin therapy and thromboembolic complications. Lupus (2005) 0.85
Mutagenic consequences of the incorporation of 6-thioguanine into DNA. Biochem Pharmacol (1997) 0.84
Rituximab in chronic inflammatory demyelinating polyneuropathy associated with diabetes mellitus. J Neurol Sci (2007) 0.84
Mitoxantrone therapy in multiple sclerosis and acute leukaemia: a case report out of 644 treated patients. Mult Scler (2004) 0.83
Associations between cyclosporine therapy and interstitial fibrosis in renal allograft biopsies. Transplantation (1988) 0.82
Azathioprine therapy in steroid-dependent patients with Crohn disease: results of a 10-year longitudinal follow-up study. Med Sci Monit (2009) 0.82
Analysis of gene mutations and clastogenicity following short-term treatment with azathioprine in MutaMouse. Environ Mol Mutagen (1999) 0.82
Complete remission induced by rituximab in refractory, seronegative, muscle-specific, kinase-positive myasthenia gravis. J Neurol Neurosurg Psychiatry (2007) 0.81
Long-term treatment of generalised myasthenia gravis with FK506 (tacrolimus). J Neurol Neurosurg Psychiatry (2005) 0.81
Retrospective analysis of the use of cyclosporine in myasthenia gravis. Neurology (2000) 0.81
Rituximab efficacy in CIDP associated with idiopathic thrombocytopenic purpura. Muscle Nerve (2008) 0.80
Opposite changes in serum soluble CD8 in patients at the active stages of Graves' and Hashimoto's diseases. Thyroid (1997) 0.80
Brain metastases from colorectal cancer: risk factors, incidence, and the possible role of chemokines. Clin Colorectal Cancer (2009) 1.20
Atypical teratoid/rhabdoid tumor of the spine in an adult: case report and review of the literature. J Neurooncol (2007) 1.18
Recurrent meningioma: salvage therapy with long-acting somatostatin analogue. Neurology (2007) 1.16
Postoperative stereotactic radiosurgery without whole-brain radiation therapy for brain metastases: potential role of preoperative tumor size. Int J Radiat Oncol Biol Phys (2012) 1.16
Genetics of glioblastoma: a window into its imaging and histopathologic variability. Radiographics (2011) 1.06
Preliminary assessment of a neuropathic pain treatment and referral algorithm for patients with cancer. J Pain Symptom Manage (2011) 1.01
Phase 2 study of dose-intense temozolomide in recurrent glioblastoma. Neuro Oncol (2013) 0.96
Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: Morphological findings. Hum Pathol (2006) 0.94
Immunotherapy for the treatment of glioblastoma. Cancer J (2012) 0.93
Efficacy of thalidomide for the treatment of amyotrophic lateral sclerosis: a phase II open label clinical trial. Amyotroph Lateral Scler (2009) 0.93
Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm. Clin Endocrinol (Oxf) (2006) 0.92
A Phase II trial of paclitaxel and topotecan with filgrastim in patients with recurrent or refractory glioblastoma multiforme or anaplastic astrocytoma. J Neurooncol (2005) 0.90
Aggressive silent corticotroph adenoma progressing to pituitary carcinoma: the role of temozolomide therapy. Hormones (Athens) (2011) 0.90
Ex vivo expansion of tumor specific lymphocytes with IL-15 and IL-21 for adoptive immunotherapy in melanoma. Cancer Lett (2009) 0.89
Seizure prognosis of patients with low-grade tumors. Seizure (2012) 0.89
Anti-VEGF therapy in pituitary carcinoma. Pituitary (2012) 0.88
Gene expression profile of peripheral blood lymphocytes from renal cell carcinoma patients treated with IL-2, interferon-α and dendritic cell vaccine. PLoS One (2012) 0.86
Temozolomide in aggressive pituitary adenomas and carcinomas. Clinics (Sao Paulo) (2012) 0.85
A phase 2 trial of verubulin for recurrent glioblastoma: a prospective study by the Brain Tumor Investigational Consortium (BTIC). J Neurooncol (2014) 0.84
Serine/threonine kinase 17A is a novel candidate for therapeutic targeting in glioblastoma. PLoS One (2013) 0.82
Regulatory T-cells and associated pathways in metastatic renal cell carcinoma (mRCC) patients undergoing DC-vaccination and cytokine-therapy. PLoS One (2012) 0.81
Effect of temozolomide in a patient with recurring oncocytic gonadotrophic pituitary adenoma. Hormones (Athens) (2010) 0.80
Management of newly diagnosed glioblastoma: guidelines development, value and application. J Neurooncol (2009) 0.79
Dye dilution proliferation assay: application of the DDPA to identify tumor-specific T cell precursor frequencies in clinical trials. Immunol Invest (2007) 0.79
FLAIR lesion volume in multiple sclerosis: relation to processing speed and verbal memory. J Int Neuropsychol Soc (2005) 0.78
The mitogen-activated protein kinase pathway plays a critical role in regulating immunological properties of BRAF mutant cutaneous melanoma cells. Melanoma Res (2016) 0.77
Thymoma-associated paraneoplastic encephalitis (TAPE): diagnosis and treatment of a potentially fatal condition. J Thorac Cardiovasc Surg (2010) 0.77
Brain metastases from colorectal cancer: risk factors, incidence, and the possible role of chemokines. Clin Colorectal Cancer (2009) 0.77
A phase II trial of oral gimatecan for recurrent glioblastoma. J Neurooncol (2012) 0.76
Stem cells in brain tumorigenesis and their impact on therapy. Curr Stem Cell Res Ther (2011) 0.76
Vaccine-based immunotherapy for glioblastoma. CNS Oncol (2013) 0.75